Author: I.G. Bereznyakov, Kharkiv Medical Academy of Postgraduate Education, Ukraine
The aim is to analyze the use of fosfomycin-trometamol (FT) in the treatment of acute lower uncomplicated urinary tract infections.
The analysis of data in literature was performed regarding: FT antibacterial activity spectrum; immunomodulatory properties of the drug and its action on biofilms; pharmacokinetics of FT after oral administration; results of microbiological tests of pathogens sensitivity to FT in urinary tract infections; sensitivity of multiresistant strains of bacteria to the drug; results of clinical trials of FT in patients with acute cystitis; drug safety; fosfomycin in current international and national guidelines for the treatment of acute uncomplicated cystitis; FT on the Ukrainian market.
Fosfomycin’trometamol is the bactericidal antibiotic of choice in the treatment of acute lower uncomplicated urinary tract infections and, at the same time, is the only one with the course dose to be taken once. A unique mechanism of action, with inhibition of the outer membranes synthesis of bacterial cells at an early stage, results in extremely rare occurrence of co’resistance to antibiotics of other classes in pathogens. The results of clinical and microbiological studies indicate high efficiency of FT in acute uncomplicated cystitis, including cases caused by «problematic» multi’resistant strains. FT tolerance is comparable to that of comparison drugs in non’pregnant women and is better in pregnant women. Fosfomed and some other generic FT drugs are available on the Ukrainian market.
Key words: fosfomycin’trometamol, lower urinary tract infections, pregnancy.